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Antibody-directed enzyme prodrug therapy is a targeted therapy in which a prodrug is activated selectively at the tumour site
by an enzyme, which has been targeted to the tumour by an antibody (antibody-enzyme conjugate). Previous clinical trials
have shown evidence of tumour response, however, the activated drug had a long half-life, which resulted in dose-limiting
myelosuppression. Also, the targeting system, although giving high tumour to blood ratios of antibody-enzyme conjugate
(10000:1) required administration of a clearing antibody in addition to the antibody-enzyme conjugate. The purpose of this
current study therefore was to attempt tumour targeting of the antibody-enzyme conjugate without the clearing antibody, and
to investigate a new prodrug (bis-iodo phenol mustard, ZD2767P) whose activated form is highly potent and has a short half-
life. Twenty-seven patients were treated with antibody-directed enzyme prodrug therapy using A5CP antibody-enzyme
conjugate and ZD2767P prodrug, in a dose-escalating phase I trial. The maximum tolerated dose of ZD2767P was reached at
15.5 mg m
726three administrations with a serum carboxypeptidase G2 level of 0.05 U ml
71. Myelosuppression limited dose
escalation. Other toxicities were mild. Patients’ quality of life was not adversely affected during the trial as assessed by the
measures used. There were no clinical or radiological responses seen in the study, but three patients had stable disease at day
56. Human anti-mouse antibody and human anti-carboxypeptidase G2 antibody were produced in response to the antibody
enzyme conjugate (A5CP). The antibody-enzyme conjugate localisation data (carboxypeptidase G2 enzyme levels by HPLC on
tumour and normal tissue samples, and gamma camera analysis of I-131 radiolabelled conjugate) are consistent with
inadequate tumour localisation (median tumour: normal tissue ratios of antibody-enzyme conjugate of less than 1). A
clearance system is therefore desirable with this antibody-enzyme conjugate or a more efﬁcient targeting system is required.
ZD2767P was shown to clear rapidly from the circulation and activated drug was not measurable in the blood. ZD2767P has
potential for use in future antibody-directed enzyme prodrug therapy systems.
British Journal of Cancer (2002) 87, 600–607. doi:10.1038/sj.bjc.6600517 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: monoclonal antibody; ADEPT; carcinoembryonic antigen (CEA); colorectal neoplasm; clinical trial
Colorectal cancer is the second most common cause of cancer
death in the UK. Conventional chemotherapy is unable to cure
patients with advanced or metastatic disease, so there is an urgent
need to develop novel therapies. Systemic treatments for most solid
tumours are limited by lack of speciﬁcity and the emergence of
drug resistance. Antibody directed enzyme prodrug therapy
(ADEPT) is designed to overcome these obstacles to successful
therapy (Bagshawe et al, 1988).
ADEPT is a two step targeted therapy. The ﬁrst step involves the
administration of an antibody-enzyme conjugate, which targets the
tumour. This is followed by the administration of a prodrug, which
is activated by the enzyme to form a chemotherapeutic agent at the
site of the tumour. Each enzyme molecule can activate many mole-
cules of prodrug, which results in large amounts of drug generated
at the tumour (ampliﬁcation effect). As the activation of prodrug
occurs extracellularly, active drug can also diffuse to neighbouring
cells, killing them with a bystander effect.
Previous clinical trials of ADEPT have used A5CP, which
consists of a F(ab)2 fragment of a mouse monoclonal antibody
to CEA (A5B7) linked to the bacterial enzyme carboxypeptidase
(CPG2), as the antibody-enzyme targeting agent. This was used
in combination with a benzoic acid mustard prodrug, CMDA,
which is activated by cleavage of its glutamate moiety (Bagshawe
et al, 1995; Napier et al, 2000). These trials have shown evidence
of tumour response (Bagshawe et al, 1995; Napier et al, 2000),
however, toxicity was thought to have resulted from the long
half-life of the activated drug, which diffused back into the circula-
tion to cause myelosuppression (Springer et al, 1993; Martin et al,
1997). Also, the targeting system, although giving high tumour to
blood ratios of antibody-enzyme conjugate (10 000:1), was
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monoclonal clearing antibody directed to the active site of CPG2
(Napier et al, 2000). This antibody was galactosylated to accelerate
its clearance from the circulation (Sharma et al, 1990, 1994).
The purpose of this current study was to investigate tumour
targeting of the antibody-enzyme conjugate (A5CP) without the
clearing antibody, and to study a new prodrug (bis-iodo phenol
mustard, ZD2767P) whose activated form has a short half-life
and is highly potent. ZD2767P was designed to overcome the
problem of long-acting active drug diffusing from tumour into
the circulation and causing myelosuppression (Springer et al,
1995; Blakey et al, 1996). The study was designed to incorporate
conventional phase I clinical trial measures, including toxicity
and pharmacokinetics, with mechanistic studies in order to achieve
a better understanding of ADEPT, and to identify potential
improvements for future ADEPT systems.
MATERIALS AND METHODS
Materials
A5CP was manufactured by Lonza Biologics, and supplied by
AstraZeneca Pharmaceuticals. A5CP was formulated as 50, 159 or
150 unit per ml sterile aqueous solution packed in neutral (Type
1) glass vials with a nominal volume of 5 ml. A5CP was diluted
in 0.9% sodium chloride and administered over 2 h as a 500 ml
intravenous (i.v.) infusion.
Radiolabelling of A5CP was performed using 370 MBq of
131Ib y
the N-bromo-succinamide/L-tyrosine technique (Adam, 1989).
Thin layer chromatography (TLC) was performed to assess iodine
incorporation and antigen binding was assessed using a CEA
column.
ZD2767P was manufactured and supplied by AstraZeneca as a
non-sterile product containing 610 mg of crystalline ZD2767P
hydroiodide per vial (which was equivalent to 500 mg of
ZD2767P free base). Ten ml of sodium bicarbonate solution was
added to this and ZD2767P hydroiodide salt was converted to
ZD2767P di-sodium salt. The ﬁnal solution contained 53.7 mg
ml
71 of ZD2767P di-sodium salt, which was equivalent to 50
mg ml
71 of free base. ZD2767P was administered as three bolus
doses an hour apart, into a fast running i.v. infusion of Dextrose
5%, through a central (Hickman) line.
Methods
A5CP Pharmacokinetics Blood samples were taken at 5 min, 1,
2, 3, 5 h and then daily after A5CP administration to assess clear-
ance of A5CP from blood. The catalytic activity of CPG2 in serum
was used to prospectively measure clearance of A5CP. This was
performed initially by spectrophotometric methotrexate reduction
assay (McCulloch et al, 1971; Hughes et al, 1982), and later by
the semi-automated Cobas Fara II centrifugal analyser (Cobas
assay). CPG2 enzyme levels below 0.05 U ml
71 were conﬁrmed
by a methotrexate reduction assay on HPLC (Blakey et al, 1996).
The clearance of
131I-radiolabelled A5CP was assessed retrospec-
tively by gamma counting of plasma samples. The clearance of
A5CP by both CPG2 enzyme levels and
131I-radioactivity was then
graphed and a biexponential model ﬁtted to calculate alpha and
beta half-lives.
Serum CPG2 enzyme levels on prodrug day A blood sample
was taken immediately prior to prodrug administration and was
analysed retrospectively by methotrexate reduction assay on HPLC
to conﬁrm the CPG2 enzyme level in serum.
CPG2 enzyme levels in tumour and normal tissue In patients
who gave their consent, tumour or bone marrow biopsies were
taken on prodrug day to assess A5CP localisation. These samples
were analysed for CPG2 enzyme levels by HPLC using a metho-
trexate reduction assay (Blakey et al, 1996).
Gamma camera imaging Patients who received
131I-radio-
labelled A5CP were imaged daily on an ADAC Vertex Plus dual
headed gamma camera. The imaging consisted of planar and
SPECT acquisitions. SPECT images were reconstructed using
ADAC ﬁltered-back projection software and were corrected for
decay, attenuation and Compton scatter. Analysis was then
performed using region of interests placed in areas of tumour
and normal tissue (heart, lung, liver) as previously described
(Green et al, 1990). The per cent injected radioactivity dose per
kg was calculated for each of these tissues. The enzyme level
(U g
71) was estimated in the tumour for prodrug day, by model-
ling the data as a mono-exponential clearance and extrapolating
to prodrug day.
Immunogenicity Blood was taken from patients prestudy and at
weekly intervals post A5CP administration for 8 weeks. Human
anti-mouse antibody (HAMA) and human anti-CPG2 antibody
(HACPG2A) response was measured by ELISA and compared with
known positive and negative controls (Sharma et al, 1992).
ZD2767P (prodrug) pharmacokinetics ZD2767P prodrug
concentrations in plasma were measured by HPLC. Plasma samples
were taken for prodrug level estimations 2 min after the ﬁrst and
second prodrug injection, and at 2, 5, 10, 15, 30 and 60 min after
the third prodrug injection. A complete pharmacokinetic proﬁle
including concentration of ZD2767P extrapolated back to time 0
min (C0), volume of distribution in the body at steady state
(Vss), area under the curve (AUC) and elimination half-life of
prodrug (T1/2) was determined for each evaluable patient using a
non-compartmental model and WinNonlin software.
Comet assay The short half-life of the active drug of ZD2767P
prevented it being directly measured in the clinical trial. However,
as it is an alkylating agent, its lethality to cells is via the formation
of DNA interstrand cross-links. The presence of DNA interstrand
crosslinks was measured in the trial by a single cell comet assay.
This was performed on tumour biopsy specimens and bone
marrow aspirates. Peripheral blood lymphocytes taken at the same
time as the biopsy were used as controls. All tumour or bone
marrow biopsies were performed on the day of receiving prodrug,
1–2 h after receiving the last prodrug injection (Webley et al,
2001).
Toxicity assessment Toxicity was assessed using National Cancer
Institute Common Toxicity Criteria (NCI-CTC) (National Cancer
Institute, 1988).
Response assessment Response was assessed using standard
WHO response criteria, based on change in maximal bidimensional
diameters of lesions. Survival times were calculated from the start
of treatment.
Quality of life Patient’s quality of life was assessed during the
trial using the Functional Assessment of Chronic Illness Therapy
(FACIT G) (Cella et al, 1993) core questionnaire. Overall wellbeing
was measured using the Trial Outcome Index (TOI) which is the
combined scores of the functional and physical domains with the
site speciﬁc subscales. Fatigue was measured using the symptom
speciﬁc subscale for fatigue. Questionnaires were given to patients
within 1 week of commencing on the clinical study and at days 7,
14, 21, 42 and 56 following the treatment. Non-parametric analyses
were carried out using the Statistical Package for the Social
Sciences (SPSS) version 8. The Wilcoxon Signed ranks test was
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test to measure differences overall.
Patients
The trial had Local Ethics Committee (LREC), Department of Health
Medicines Controls Agency, and Administration of Radioactive
Substances Committee (ARSAC) approval. It was performed accord-
ing to the principles of Good Clinical Practice, under the auspices of
Cancer Research UK Phase I/II Clinical Trials Group. Cancer
Research UK Drug Development Ofﬁce monitored the clinical data.
All patients gave written informed consent for the study. The
eligibility criteria were unresectable, locally recurrent or metastatic
colorectal carcinoma or other CEA expressing tumour; no anti-
tumour treatment in the previous 4 weeks; bidimensionally
measurable disease by plain X-ray, CT or ultrasound scan; age
518 years; life expectancy 54 months; WHO performance status
0, 1 or 2; and normal haematological, biochemical, renal and hepa-
tic function unless abnormal due to tumour. Pre-treatment serum
CEA levels were required to be between 10 mgl
71 and 1000 mgl
71:
if the serum CEA was not raised, then CEA had to be demon-
strated by immunohistochemistry on tumour specimens (Boxer et
al, 1994). Patients were excluded if they had pre-existing HAMA
to A5B7, or HACPG2A; the presence of active brain metastasis;
if they were a poor medical risk; HIV, Hep B or C positive; or
pregnant or lactating.
All patients had an intradermal skin test to the A5CP conjugate
performed and would have been excluded if they formed a positive
reaction to it. All patients had received previous conventional
chemotherapy or radiotherapy, and had either relapsed or showed
no response. Preclinical studies indicated the need for the ZD2767P
prodrug to be injected into a large bore vein, so all patients had a
double lumen Hickman catheter inserted; in most cases this was
into the subclavian vein. All patients who received
131I-radio-
labelled conjugate also received thyroid blocking with potassium
iodide 50 mg q.d.s. for 10 days commencing 1 day prior to the
administration of the radiolabelled product. Patients could receive
metoclopramide as an antiemetic if required after the administra-
tion of prodrug.
Treatment schedule
3000 U m
72 of A5CP in 500 ml of 0.9% sodium chloride was
given over 2 h on day 0. 250 U of A5CP was radiolabelled with
131I 370 MBq and administered as a slow i.v. bolus over 2 min
at the end of the infusion. Daily serum CPG2 measurements were
performed until the serum CPG2 enzyme levels fell below a pre-
determined value. This level was initially 0.20 U ml
71 (patients
1, 3–9), however because of early toxicity it was lowered to 0.10
Um l
71 (patients 2, 10–22) then 0.05 U ml
71 for all subsequent
patients. Once this level was achieved, ZD2767P prodrug was
administered as three bolus injections, 1 h apart, each over 5
min into a fast running 5% dextrose drip. Patients were then
followed up for a period of at least 8 weeks from the time of
conjugate administration.
RESULTS
Study population
Twenty-seven patients (21 males and six females) were treated with
ADEPT. One further patient was recruited but not treated, due to
becoming ineligible after registration. The median age was 56 years
(range 32–74 years). Twenty-ﬁve patients had advanced colorectal
cancer, one patient had a CEA expressing carcinoma of the
pancreas, and one patient had CEA expressing non-small cell lung
cancer. The median number of prior chemotherapy regimens
before entering the study was 2 (range 0–7). Fifteen patients
(55%) had a WHO performance status of 0, 11 (41%) had a
performance status of 1 and one patient (4%) had a performance
status of 2 at the time of entry into the study.
MTD/DLT/toxicity
The dose of A5CP remained ﬁxed throughout the study, with the
dose of ZD2767P being escalated until maximum tolerated dose
(MTD) was established. The start dose of ZD2767P was 4.9 mg
m
726three doses. At 18.63 mg m
72 6three doses, drug-related
dose limiting toxicity (DLT) occurred which stopped further dose
escalation. This consisted of Grade 4 thrombocytopenia in two out
of ﬁve patients. One patient at a dose of 18.63 mg m
72 also had a
prolonged period of neutropenia. The ZD2767P dose was subse-
quently reduced to 15.5 mg m
72 6three doses in order to
establish the MTD.
From dose level 4.9 to 15.5 mg m
72 treatment was well toler-
ated with mainly Grade I–II haematological drug-related adverse
events (AEs) (Table 1). Overall 12 patients experienced Grade I–
IV drug related thrombocytopenia, with a median nadir of 4
weeks (27.5 days), and eight patients experienced Grade I–IV
drug related leucopenia, with a median nadir of 6 weeks (41.5
days). Other side-effects were mild. Sixteen (59%) patients had
grade I drug related nausea and one (4%) patient had grade II
nausea. Eleven (41%) patients had grade I or II malaise, which
was considered at least possibly drug related. Two (7%) patients
had grade III malaise, again considered possibly related to the
ADEPT treatment. Six (22%) patients developed a fever in the
absence of infection which may have been related to the ADEPT
treatment.
Patients who had grade II or greater drug related toxicity with
ADEPT were invited to participate in receiving ZD2767P alone,
in order to assess its toxicity. Three patients agreed to have
ZD2767P alone, and these patients were followed for a further
6–8 weeks. One patient developed Grade 1 nausea after
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Table 1 Highest NCI-CTC grade of haematological toxicity attained for
each patient according to ZD2767P dose level
A
NCI-CTC toxicity grade
(WBC)
0 I II III IV
4.9 mg m
72 41
6.0 mg m
72 1
6.37 mg m
72 4
8.28 mg m
72 3
12.42 mg m
72 2
15.5 mg m
72 42 1
18.63 mg m
72 22 1
B
NCI-CTC toxicity grade
(platelets)
0 I II III IV
4.9 mg m
72 41
6.0 mg m
72 1
6.37 mg m
72 31
8.28 mg m
72 21
12.42 mg m
72 11
15.5 mg m
72 421
18.63 mg m
72 111 2
(A) WBC Toxicity by ZD27667P dose level. (B) Platelet toxicity by ZD2767P dose
level.
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toxicities. The third patient had a transient Grade 1 leucopenia
and neutropenia, which were considered possibly related to
ZD2767P.
A5CP pharmacokinetics
A5CP clearance from the blood was measured by serial CPG2
serum enzyme levels and by clearance of I
131-radiolabelled A5CP.
Three batches of A5CP were used in the trial (Campaign 1, 2
and 4). The b half-life of A5CP by clearance of CPG2 enzyme levels
from serum was Campaign 1=8.95 h (spec assay), Campaign
2=11.8 h (cobas) and Campaign 4=15.49 h (cobas). The b half-life
of A5CP by clearance of
131I-radiolabelled A5CP was Campaign
1=5.77 h, Campaign 2=5.08 h and Campaign 4=11.77 h.
Serum CPG2 enzyme levels on prodrug day
The median serum CPG2 enzyme level on prodrug day was 0.033
Um l
71 (range 0.013–0.152 U ml
71) by Spec/Cobas and 0.037 U
ml
71 (range 0.011–0.180 U ml
71) by HPLC. The number of days
until prodrug administration was a median of 3 days (range 2–9
days).
CPG2 enzyme levels in tumour and normal tissue
The median CPG2 enzyme level in tumour biopsies was 0.010 U
g
71 (range 0–0.208 U g
71) on prodrug day (n=7) (Table 2a).
The median CPG2 enzyme level in normal tissue was 0.005 U
g
71 (range 0–0.062 U g
71)( n=5) (Table 2b). The median ratio
of CPG2 enzyme in tumour:blood on prodrug day was 0.4 : 1
(range 0–10.4 : 1) (Table 2c).
Gamma camera imaging
Eighteen patients had SPECT scans performed which were suitable
for quantitative analysis. The overall median per cent injected dose
per kg of radiolabelled conjugate in the tumour on prodrug day
was 0.185 per cent per kg, range 0.0006–1.05 per cent per kg
(Figure 1). The median number of estimated enzyme units in the
tumour at the time of prodrug administration was 0.010 U g
71,
range 0.000037–0.054 U g
71. The median uptake of radiolabelled
conjugate in heart (estimate for bloodpool) remained higher than
in tumour for the 5, 24 and 46 h time-points, and for normal liver
it remained higher than tumour at all measured time-points. These
results are consistent with the low median tumour to blood ratio
of enzyme activity of 0.4 : 1 attained by HPLC assay.
Immunogenicity
Twenty-six out of 27 patients who received A5CP had sufﬁcient
blood samples taken for analysis for immunogenicity. All of these
patients developed a positive HAMA response following the single
administration of A5CP. The median number of days until devel-
oping a positive HAMA was 14 days (range 7–36 days). All
patients except one (patient #13) developed a positive HACPG2A
response. The overall median number of days until developing a
positive HACPG2A was 15 days (range 7–50 days).
ZD2767P (prodrug) pharmacokinetics
All 27 patients had blood samples taken for pharmacokinetic analy-
sis, however in some patients a full pharmacokinetic proﬁle could
not be obtained due to technical problems, in particular haemolysis
of blood samples resulting in inaccurate and incomplete data.
Table 3 is a summary of the non-compartmental pharmacokinetic
values calculated at each dose level for all patients in which reliable
analysis could be performed. Average AUC values increased with
increasing doses. The mean measured half-life of ZD2767P in
plasma at the MTD was 14.5 min. The values for volume
of distribution did not appear dose dependent.
Figure 2 shows the mean plasma prodrug elimination proﬁles
following the third administration of prodrug, for each dose group
of patients. This ﬁgure conﬁrms that the prodrug is essentially
cleared for all dose levels within 60 min of administration. Figure
3 shows the variation of ZD2767P levels after each of the three
administrations of prodrug, at each different prodrug dose. There
is no obvious accumulation of prodrug in the 1 h interval between
doses.
Three patients who experienced toxicity with full ADEPT were
given prodrug alone, and had pharmacokinetic studies performed.
Patients 3 (4.9 mg m
72) and 19 (18.63 mg m
72) had PK para-
meters that were broadly similar to those when each was given
ADEPT (although data for patient 3 were limited).
Comet assay
The tumour biopsy of one patient (patient 15) had an 80%
reduction in tail moment in the comet assay thereby indicat-
ing the presence of DNA interstrand cross-links (Webley et al,
2001). The circulating lymphocytes in the same patient did
not have DNA interstrand cross-links. Eight other patients
had comet assays performed on tumour biopsy specimens
(n=4) and normal tissue (n=4). There was no signiﬁcant
reduction in tail moment seen in these samples, or in the
circulating blood lymphocytes measured as controls in these
eight patients.
Tumour response
Of the 27 patients, 26 were evaluated for response. There were no
objective responses in this study. Three patients had stable disease
at day 56.
Quality of life
Participation in ADEPT did not adversely affect patients’ quality of
life as measured by the Functional Assessment of Chronic Illness
Therapy Trial Outcome Index. There were no signiﬁcant differ-
ences in the amount of fatigue experienced but it could be seen
that the fatigue burden varied between patients. Patient’s emotional
wellbeing was not adversely affected and individual patient scores
remained stable.
DISCUSSION
The purpose of this ADEPT trial was to investigate a new prodrug
(bis-iodo phenol mustard, ZD2767P) whose activated form is
highly potent and has a short half-life, and to study tumour target-
ing of A5CP without a clearance system.
The trial was designed in a mechanistic fashion to allow the
determination of whether conditions for effective therapy with
ADEPT were met. This included the measurement of CPG2
enzyme levels in serum, tumour and normal tissues,
131I-labelled
conjugate biodistribution studies, immunogenicity assessment,
prodrug pharmacokinetic analysis and comet assay for DNA inter-
strand cross-links.
Toxicity, efﬁcacy and quality of life
The toxicity of ADEPT consisted mainly of myelosuppression,
which proved dose limiting. Myelosuppression occurred with a
nadir for thrombocytopenia 4 weeks and a nadir for neutropenia
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grade 4 neutropenia at the ﬁrst dose level (4.9 mg m
72–Patient
no. 3), however reducing the serum enzyme level at which prodrug
was given from 0.2 to 0.05 U ml
71 meant further dose escalation
was possible. DLT was established at a ZD2767P dose of 18.63 mg
m
72 63 administrations and MTD at 15.5 mg m
72 63 adminis-
trations. Other toxicities from ADEPT were mild.
Three patients with drug related toxicity from full ADEPT had
ZD2767P prodrug alone administered. This was well tolerated with
only a few transient Grade I ‘possibly’ drug related toxicities
experienced.
There were no tumour responses but the mechanistic studies
(below) indicate the reasons for this and indicate the level of
improvement required before efﬁcacy would be expected.
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Table 2 Biopsies performed on day of administration of ZD27667P prodrug in patients in ADEPT study. The CPG2 enzyme levels in tumour and serum
were measured by HPLC
CPG-2 Enzyme level
(HPLC)
Tumour Serum Tumour/serum Phosphor
Patient Site Histology (U g
71)( U m l
71) ratio Imager
01 Colon tumour 0.014 0.028 0.5:1 negative
02 Colostomy tumour/necrosis 0.061 0.041 1.5:1 negative
05 Liver metastases tumour undetectable 0.011 0 negative
06 Liver metastases not done 0.208 0.020 10.4:1 negative
15 Liver metastases tumour 0.010 0.025 0.4:1 positive
23 Liver metastases tumour islands 0.000 0.097 0 negative
25 Liver metastases normal 0.000 0.180 0 not performed
liver/necrotic
tumour debris
B
CPG2 Enzyme level
(HPLC)
Normal tissue Serum Normal tissue/ Phosphor
Patient Site Histology (U g
71)( U m l
71) serum ratio Imager
11 Bone marrow not available 0.005 0.036 0.1:1 not applicable
13 Subcutaneous node subcutaneous tissue 0.062 0.022 2.8:1 negative
18 Bone marrow not available 0.001 0.012 0.1:1 not applicable
19 Liver metastases normal liver 0.049 0.077 0.6:1 negative
22 Bone marrow not available 0.000 0.050 0:1 not applicable
C
Median CPG2 Median ratio
enzyme level Range to serum Range
Serum (n=27) 0.037 U ml
71 0.011–0.180 U ml
71
Tumour biopsy (n=9) 0.010 U g
71 0–0.208 U g
71 0.4:1 0–10.4:1
Normal tissue (n=5) 0.005 U g
71 0–0.062 U g
71 0.1:1 0–2.8:1
(A) Tumour biopsies performed on prodrug day. (B) Normal tissue biopsies taken on prodrug day. (C) Summary of median CPG2 enzyme levels in serum, tumour and normal
tissue on prodrug day.
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ment as measured by the Functional Assessment of Chronic Illness
Therapy Trial Outcome Index. There were no signiﬁcant differ-
ences in the amount of fatigue experienced, but it could be seen
that the fatigue burden varied between patients. Patients’ emotional
wellbeing was also not adversely compromised.
Mechanistic study
Studying the individual components in terms of their distribution
and function facilitates developments of such a complex therapy
system. It was also possible to monitor the different components
of ADEPT through the course of therapy.
In this ADEPT system the median tumour : blood ratio of anti-
body-enzyme conjugate at the time of prodrug administration was
0.4 : 1. The amount of enzyme reaching the tumour was a median
of 0.010 U g
71 (enzyme levels in tumour biopsies, and gamma
camera data), too low for optimal prodrug activation in mouse
tumour model systems. It has been possible to achieve adequate
tumour levels of enzyme (0.5 U g
71) with high tumour blood
ratios (410 000:1) in a previous clinical study in which a galac-
tosylated clearing antibody was used to accelerate clearance of
conjugate from the blood (Napier et al, 2000). This previous study
did, however, use higher amounts of antibody-enzyme conjugate
(10 000 U m
72) and the prodrug was given at an earlier time-
point (48 h), so the difference in enzyme levels is at least
partially attributable to these factors.
Overall, in this trial, the tumour biopsy CPG2 enzyme data by
HPLC and gamma camera dosimetry correlated well, indicating
the robust nature of these techniques. A5CP serum half-life was
measured by CPG2 enzyme activity and by clearance of radiola-
belled A5CP. The CPG2 assays (spectrophotometric/Cobas) are
functional measures of antibody-enzyme conjugate, which depend
on the presence of intact CPG2. They are clinically relevant as they
determine whether prodrug can be safely administered to avoid
activation in the peripheral circulation. Measurement of radioactiv-
ity clearance may reﬂect not only intact antibody-enzyme, but also,
fragments of antibody-enzyme with radioactivity attached. Radiola-
belled material with low or absent enzyme activity may have been
potentially metabolised in vivo, or damaged by the radiolabelling
process, artiﬁcially shortening the circulating half-life. The shorter
half-life of A5CP obtained by measuring clearance of radioactivity
as opposed to functional CPG2 enzyme in this trial is therefore
likely to be due to clearance of iodinated breakdown products of
131I-radiolabelled A5CP.
Initially a spectrophotometric assay was used to prospectively
measure serum CPG2 enzyme levels, and later a Cobas assay was
adopted. This change was initiated as a result of sensitivity
problems with the spectrophotometric assay at enzyme levels below
0.05 U ml
71. The two assays gave similar results above this level.
The HPLC assay provides the most accurate measurement of CPG2
enzyme level, however it was not practical to run this assay on a
daily basis in a prospective manner to determine CPG2 enzyme
levels for treatment in the clinical trial. The HPLC assay was run
retrospectively in all patients on the pre-prodrug enzyme level in
order to conﬁrm the estimation attained on the spectrophoto-
metric or Cobas assays. A rapid HPLC methotrexate reduction
assay has now been developed which will supersede both the spec-
trophotometric and Cobas assays for future clinical trials.
The formation of HAMA and HACPG2A occurred in all
patients except one (Patient no. 13–no HACPG2A formation).
CPG2 is of bacterial origin, and is used in ADEPT systems because
it has no human equivalent that may lead to endogenous enzyme
activation. The A5B7 F(ab)2 antibody is murine. The immunogeni-
city of A5CP limits potential for repeated therapy although
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Figure 3 Plasma levels of ZD2767P prodrug measured 2 min after doses
1, 2 and 3. All valid values are included. Individual patients are not identiﬁed.
Only 4 values are shown for the dose group 18.63 mg m
72 after dose
three as the pharmacokinetic calculations for one patient were made start-
ing from the 5 min time point.
Table 3 Summary of the non-compartmental pharmacokinetic parameters calculated for all suitable patients
ZD2767P
dose Half-life AUC Clearance Cmax Vss
(mg m
72) Patient (mins) (mgm l
71 min
71) (ml min
71)( mgm l
71) (l)
4.9 01, 03, 04 Mean 6.4 8.0 1253 1.1 9.4
s.d. 1.3 2.1 495 0.4 5.2
Range 3.6–6.2 5.7–9.8 915–1822 0.6–1.3 4.8–15
6.37 02, 09, 10 Mean 5.4 10.6 1142 1.4 8.4
s.d. 1.1 1.8 162 0.3 2.3
Range 4.1–6.2 8.6–11.9 1026–1327 1.1–1.7 6.0–10.5
12.42 16 4.7 33 734 3.7 5.0
15.5 22, 23, 24, 25 Mean 14.5 41 842 3.4 13.4
26, 27, 28 s.d. 8.1 17 408 0.8 5.5
Range 7.4–30.0 19–69 409–1547 2.5–4.8 6.2–22.6
18.63 17, 18, 19, Mean 11.8 61 592 5.2 7.8
20, 21 s.d. 4.4 26 207 1.9 1.9
Range 7.8–19 36–105 365–989 2.5–7.5 5.9–10.8
Patients 5, 6, 7, 11, 12, 13, 14 and 15 are omitted due to technical problems preventing accurate analysis to be performed. Data for patient 21 (18.63 mg m
72) were generated
starting from 5 min , as the 2 min time point was invalid. (AUC – area under curve; Cmax – maximum concentration; Vss – volume at steady state; s.d. – standard deviation).
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pies in the same patient in the past (Ledermann et al, 1991;
Bagshawe et al, 1995; Bagshawe and Sharma, 1996; Napier et al,
2000).
The pharmacokinetic proﬁle of ZD2767P prodrug was measured
in blood by HPLC. The elimination half-life of ZD2767P at MTD
was 14.5 min. The active drug has such a short biological half-life
that it could not be measured in this study. An indirect measure-
ment instead used a comet assay on cells retrieved from tumour
biopsies in order to ascertain the presence of DNA interstrand
crosslinks. The active drug is an alkylating agent, and produces cell
kill by DNA interstrand crosslink formation, so the presence of
crosslinks in the tumour biopsy specimen would indicate that an
alkylating agent had been active at the tumour site. Within 30
min of the tumour biopsy specimen being taken, peripheral blood
was also taken to look for DNA crosslinks in circulating lympho-
cytes. Patient no. 15 had a biopsy of a liver metastasis of
colorectal cancer. An 80% reduction in comet tail, indicating the
presence of DNA interstrand crosslinks was demonstrated. The
circulating peripheral lymphocytes were unaffected, showing no
evidence of DNA crosslink formation. In this patient, the tumour
biopsy specimen also showed evidence of
131I conjugate localisation
on phosphor imager (Table 2a). This suggests that in this one
patient effective antibody localisation and selective prodrug activa-
tion may have occurred. This patient had radiological stable disease
at 56 days.
In summary, serum, tumour and normal tissue enzyme levels
could be monitored by direct measurement on tissue samples
and by serial quantitative gamma camera imaging of radiolabelled
antibody-enzyme conjugate. Tumour to serum enzyme ratios,
where determined, were less than one, which is inadequate for
selective prodrug activation in tumour. ZD2767P levels could be
measured serially in plasma. Evidence of prodrug activation was
obtained in tumour by comet assay and in the blood, indirectly,
by the ﬁnding of myelosuppression when prodrug was given after
antibody-enzyme and by lack of myelosuppression when prodrug
was given alone. The universal production of antibody to A5CP
prevented repeated therapy.
This study showed that it was practical to formulate and use this
relatively unstable prodrug (ZD2767P) as part of ADEPT in the
hospital clinical environment and that A5CP conjugate could be
given safely and enzyme levels could be monitored and prodrug
administered when serum enzyme levels had fallen to a safe level.
These are the essential elements of future developments of ADEPT.
This trial has also demonstrated the potential of ZD2767P for
use in further ADEPT studies, in which better tumour localisation
of antibody-enzyme can be achieved. It has shown also that it is
desirable to use a clearance system with the A5CP chemical conju-
gate, or a better antibody-enzyme targeting system should be
developed. These studies provide the basis for rational design of
improvements in ADEPT. In particular an antibody-enzyme system
is required with more efﬁcient tumour localisation and less immu-
nogenicity.
A new phase I ADEPT study has recently commenced using a
recombinant fusion protein of anti-CEA sFv fused to CPG2, in
combination with ZD2767P. In preclinical studies the new fusion
protein appears to have many of the desirable properties required
for use in ADEPT for the future (Sharma et al, 2000).
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